European Leukemia Trial Registry

less detail
Public Title Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 MDS
Scientific Title A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification
Short Title ONTARGET
Id KN/ELN LN_DEUTSC_2012_528
Trialgroup Deutsche MDS
Type of Trial single-group, open-label
Phase Phase II
Disease Myelodysplastic Syndrome(MDS) Low risk and intermedia I
Myelodysplastic Syndrome(MDS) Intermedia II and high risk
Stage of Disease .
  • The primary objectives of this study are to determine if rigosertib sodium, given orally in the form of soft gel capsules, is safe and is associated with a reduction in the number of blood transfusion units that are needed in patients with myelodysplastic syndrome (MDS) classified as Low or Intermediate-1 (Int-1) (any cytogenetics) or trisomy 8 Intermediate 2 (Int-2) in the International Prognostic Scoring System (IPSS) who are transfusion-dependent. Rigosertib will be taken only on days 1 to 14 of the 21-day cycle.
Inclusion Criteria
  • Diagnosis of MDS confirmed by bone marrow aspirate and/or biopsy within 6 weeks prior to first dose of study drug according to World Health Organization (WHO) or French-American-British (FAB) classification
  • MDS classified as Low risk or Int-1 risk (any cytogenetics) or Trisomy 8 Int-2 risk, according to IPSS classification
  • Transfusion dependency defined by at least 4 units of RBC administered within 8 weeks before baseline
  • Off all other treatments for MDS (azacitidine, decitabine, lenalidomide, chemotherapy, immunosuppressive agents) for at least 4 weeks
  • ECOG performance status of 0, 1 or 2
Exclusion Criteria
  • Ongoing clinically significant anemia due to factors such as iron, B12, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI) bleeding, unless stabilized for 1 week after RBC transfusion
  • Serum ferritin < 50 ng/mL
  • Hypoplastic MDS (cellularity < 10%)
  • Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
  • Active infection not adequately responding to appropriate therapy
  • Total bilirubin >= 1.5 mg/dL not related to hemolysis or Gilbert's disease
  • ALT/AST >= 2.5 x upper limit of normal (ULN)
  • Serum creatinine >= 2.0 mg/dL
  • Ascites requiring active medical management including paracentesis
  • Hyponatremia (defined as serum sodium value of <130 mEq/L)
  • Female patients who are pregnant or lactating
  • Patients who are unwilling to follow strict contraception requirements
  • Female patients with reproductive potential who do not have a negative urine beta-human chorionic gonadotropin (bHCG) pregnancy test at Screening
  • Major surgery without full recovery or major surgery within 3 weeks of rigosertib treatment start
  • Uncontrolled hypertension (defined as a systolic pressure >=160 mmHg and/or a diastolic pressure >=110 mmHg)
  • New onset seizures (within 3 months prior to the first dose of rigosertib) or poorly controlled seizures
  • Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy
  • Chronic use (>2 weeks) of corticosteroids (>10 mg/24 hr equivalent prednisone) within 4 weeks of starting rigosertib
  • Investigational therapy within 4 weeks of starting rigosertib
  • Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements
Age >= 18 years
Status Closed
Start of Recruitment 01.05.2012
Target Sample Size 60
Leader Platzbecker, Prof. Dr. med., Uwe
Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Sponsors Onconova Therapeutics, Inc.
Supporters Onconova Therapeutics, Inc.
Other Registers NCT01584531
  • Number of units of red blood cell transfusions 8 weeks (Primary Outcome)
  • Number of Adverse Events (AEs) From date of randomization until 30 days after last dose of study drug
  • Bone marrow blasts 4 weeks
  • Complete blood count 4 weeks
created 25.04.2013 Sina Hehn
changed 28.08.2014 Johannes Kraus
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |